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the CC BY-NC-ND license (http://creaAbstract In the current clinical setting, many disease management options are available for
men diagnosed with prostate cancer. For metastatic prostate cancer, first-line therapies
almost always involve agents designed to inhibit androgen receptor (AR) signaling.
Castration-resistant prostate cancers (CRPCs) that arise following first-line androgen depriva-
tion therapies (ADT) may continue to respond to additional lines of AR-targeting therapies
(abiraterone and enzalutamide), chemotherapies (docetaxel and cabazitaxel), bone-
targeting Radium-223 therapy, and immunotherapy sipuleucel-T. The rapidly expanding ther-
apies for CRPC is expected to transform this lethal disease into one that can be managed
for prolonged period of time. In the past 3 years, a number of promising biomarkers that
may help to guide treatment decisions have been proposed and evaluated, including androgen
receptor splice variant-7 (AR-V7), a truncated AR lacking the ligand-binding domain (LBD) and
mediate constitutively-active AR signaling. Putative treatment selection markers such as AR-
V7 may further improve survival benefit of existing therapies and help to accelerate develop-
ment of new agents for metastatic prostate cancer. In the metastatic setting, it is important to
consider compatibility between the putative biomarker with non-invasive sampling. In this re-
view, biomarkers relevant to the setting of metastatic prostate cancer are discussed with
respect to a number of key attributes critical for clinical development of non-invasive, action-
able markers. It is envisioned that biomarkers for metastatic prostate cancer will continue to
be discovered, developed, and refined to meet the unmet needs in both standard-of-care and
clinical trial settings.
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Prostate cancer is a commonly diagnosed disease in the
Western world and metastatic prostate cancer remains
one of the leading causes of cancer death in many coun-
tries [1]. In geographical regions where prostate-specific
antigen (PSA) screening is not routinely used, prostate
cancers are less frequent, and are typically diagnosed in
later stages of the disease spectrum. Upon diagnosis of
localized prostate cancer, treatment decisions can be
made on the basis of the risk levels [2], and patients
commonly receive local therapies with curative intention,
including a variety of surgical procedures and radiation
treatments. The diagnosis of metastatic prostate cancer
may follow local treatment failures, or occur as newly
diagnosed disease without prior local therapies (Fig. 1). In
the USA, for example, roughly about 25% men diagnosed
with metastatic prostate cancer are newly diagnosed pa-
tients, while about 75% present as recurrent disease
following local therapy failures [3]. For all men with
metastatic castration-sensitive prostate cancer (mCSPC),
the stand-of-care first-line treatment has been androgen-
deprivation therapies established in the 1940s by Huggins
and Hodges [4].
Androgen deprivation therapies (ADT) are clinically
effective in controlling the disease until the development
of metastatic castration-resistant prostate cancer
(mCRPC). Prior to 2004, there was no approved therapies
for mCRPC. Today, there are six FDA-approved drugs for
mCRPC, including androgen receptor (AR)-directed thera-
pies (abiraterone acetate and enzalutamide) [5e8], taxane
chemotherapies (docetaxel and cabazitaxel) [9,10],
immunotherapy (sipuleucel-T) [11], and the bone-
targeting radiopharmaceutical radium-223 [12]. Fig. 1 il-
lustrates an overall summary of the prostate cancer dis-
ease spectrum and the treatment landscape. Among these
mCRPC therapies, abiraterone and enzalutamideare
second-line AR-targeting therapies that were developed
based on the concept that AR signaling remains a thera-
peutic target in mCRPC, due to overexpression of the AR
protein and the presence of intra-prostatic male hormones
sufficient in driving AR-dependent tumor growth [13].Figure 1 A brief summary of the disease spectrum and
treatment options for prostate cancer. ADT, androgen-
deprivation therapy; BCR, biochemical recurrence; CRPC,
castration-resistant prostate cancer; CSPC, castration-sensitive
prostate cancer; PCa, prostate cancer; Tx, treatment.The survival benefit of each individual therapies for
mCRPC has been established in definitive clinical trials
[5e9,11,12]. While the development of these new agents
for mCRPC prolonged patient survival, a number of chal-
lenges in this new treatment landscape have emerged.
First, not all men benefit from the therapies. Second, the
economic burden imposed by the new agents is a concern
especially when the benefit is unpredictable. Third,
almost invariably, treated men will stop responding and
develop resistance shortly after initiation of the thera-
pies. In most cases, the clinical benefit for a single agent
is short-lived and a decision needs to be made for the
subsequent line of therapy. Prior exposure to one or more
of the six therapies may lead to shortened duration of
response (if any) to subsequent therapies. This possible
“cross-resistance” is not well understood and the optimal
treatment sequencing remains a challenge in the clinic.
Lastly, while there is a clear need to develop new agents
to overcome drug resistance in mCRPC, clinical trial
design has become more challenging. These challenges
underscore the critical importance in clinical develop-
ment of biomarkers for mCRPC to facilitate treatment
selection.
Molecular information gleaned from patient tissue
specimens has traditionally been the prime target for
developing biomarkers for prostate cancer. Indeed, the
molecular taxonomy of primary prostate cancer and a
comprehensive mapping of potentially actionable targets
have deepened our understanding of prostate cancer and
provided essential tools needed to combat the disease
[14,15]. In most metastatic prostate cancer cases, howev-
er, a tissue-based biomarker strategy may not be feasible
for a number of reasons. Metastatic biopsies involve inva-
sive procedures that are expensive and may miss target
lesions, and the specimens may not represent the overall
tumor burden due to potential tumor heterogeneity,
although a recent study suggested limited intra-patient
heterogeneity [16]. Metastatic biopsies are currently not
part of routine clinical care of patients and sequential bi-
opsy sampling procedures will be very difficult to imple-
ment. Liquid biopsies that can be sampled non-invasively
and evaluated during the course of treatment are the so-
lution to this problem. It is well established that in patients
with metastatic prostate cancer, tumor cells (CTC) can
enter the circulation, and that circulating cell-free tumor
DNA (CtDNA) representing the tumor genome can be
captured [17].
In this review, we will highlight the most promising
biomarkers for mCRPC that have been evaluated in clinical
studies so far (see Table 1 for a summary of the markers to
be discussed), focusing on the latest evidence supporting
clinical development of CTC- and CtDNA-based detection of
AR aberrations as biomarkers for metastatic prostate can-
cer. Because both CTC and circulating tumor DNA (CtDNA)
can be obtained through a non-invasive procedure (a simple
blood draw), related markers can be evaluated sequentially
in a setting relevant to the treatments available to men
with mCRPC. If successfully developed and fully validated
analytically and clinically, the implementation of these
markers has the potential to improve the therapeutic
benefit of existing therapies, and facilitate clinical devel-
opment of new agents to overcome resistance.
Table 1 Summary of non-invasive actionable biomarkers for mCRPC evaluated in clinical studies.
Biomarker Target specimen Assay method References
AR-V7 mRNA CTC, whole blood RT-PCR, RISH [22,25e31,34]
AR-V7 protein CTC IHC [36,37]
AR DNA aberrations CtDNA Targeted sequencing, NGS [38e41,44]
DNA damage repair pathway Germline and tumor DNA (CtDNA) Targeted sequencing, NGS [42,43]
CTC, circulating tumor cells; IHC, immunohistochemistry; mCRPC, metastatic castration-resistant prostate cancer; NGS, next-
generation sequencing; RISH, RNA in situ hybridization.
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AR-V7 was initially discovered and reported in 2009 [18] and
has been characterized as one of the most important AR
splice variants due to its relative abundance and frequency
of detection in mCRPC, its constitutively active function,
and compatibility with highly specific detection. Due to
space limitations, readers are directed to a few recent re-
views for evidence supporting these assertions [19e21].
Most importantly, we recently reported preliminary findings
from a prospective clinical study evaluating whether
detection of AR-V7 in blood samples before treatment, by a
CTC-based mRNA test, was associated with lack of response
to abiraterone and enzalutamide [22]. In this study, we
enrolled a total of 71 men with mCRPC initiating either
abiraterone or enzalutamide, of which 62 were determined
to be positive for CTC and suitable for CTC-based evaluation
of AR-V7 transcript. Among the CTC-positive samples
collected at treatment baseline (n Z 62), 18 were positive
for AR-V7 mRNA. Strikingly, none of AR-V7 patients achieved
meaningful PSA response, as defined by at least 50% drop in
serum PSA levels as a result of the therapy during clinical
follow-up. The median PSA-progression-free survival (PSA-
PFS) in the AR-V7-positive cohort was 1.4 months, which
was significantly shorter than that in the AR-V7-negative
cohort (6.1 months). We also evaluated radiographic
progression-free survival (rPFS) and observed significantly
shorter rPFS in the AR-V7 positive group in comparison to
the AR-V7 negative group (2.1 months vs. 6.4 months).
Overall survival (OS) was also worse in the AR-V7 positive
men. Although our study was limited by small sample size,
the data suggest that AR-V7 was a negative prognostic
marker in men receiving abiraterone and enzalutamide, two
AR-targeting drugs that conceptually would be ineffective
in suppressing AR signaling mediated by AR-V7 [23,24].
Among the subjects (n Z 42) that were sampled
sequentially during the course of treatment, we did not
observe a change in AR-V7 status in follow-up samples in
subjects (nZ 16) tested positive at the baseline. However,
six patients with a negative AR-V7 result at the baseline
were AR-V7 positive in follow-up samples. The treatment
outcome of patients who experienced a “conversion” of
their AR-V7 status was intermediate, worse than those
showing consistently negative results but better than those
showing persistent positive results [22].
In a subsequent follow-up study, we evaluated whether
AR-V7 status can also predict treatment outcome in men
receiving taxane chemotherapies [25]. We enrolled a total of
44 men initiating either docetaxel or cabazitaxel, of which
37 were determined to the CTC-positive. Among the 37 CTC-positive men, 17 were initially AR-V7 positive at the base-
line. We observed w41% PSA response rate in the 17 AR-V7
positive patients, and 65% PSA response rate in the 20 AR-
V7 negative patients. This finding suggests that taxane che-
motherapies, unlike AR-targeting therapies, may remain
efficacious in AR-V7-positive men. Indeed, our preliminary
analysis showed that in AR-V7 positive men, taxane chemo-
therapy was more efficacious than the AR-targeting agents
on the basis of outcome measures including PSA-PFS and
rPFS, while no statistically significant difference in treat-
ment outcome by therapies were observed in the AR-V7
negative men [25]. Interestingly, a subset of AR-V7 positive
patients had no dateable AR-V7 following taxane chemo-
therapies. Future studies are warranted to further evaluate
the clinical utility of sequential AR-V7 measurements,
especially given that serial measurements across many
different treatments are clinically feasible [26]. Collectively,
studies conducted in a single-institution setting suggest that
predictive utility of AR-V7 is specific to AR-targeting agents
and a positive detection of AR-V7 may still be compatible
with treatments with taxane chemotherapies. These pilot
studies [22,25,26] have generated data supporting expanded
evaluation of AR-V7 as a treatment selection marker in the
standard-of-care setting.
3. Confirmatory studies involving detection of AR-
V7 transcript in blood
The pioneering study by Antonarakis et al. [22] also
established AR-V7 as a measurable target in blood samples,
and have since motivated a number of confirmatory studies
with or without enrichment of CTCs. Steinestel et al. [27]
evaluated 37 CTC-positive prostate cancer patients, of
which 18 were AR-V7 positive, using a CTC-based test
similar to that described in Antonarakis et al. [22]. Among
the 22 patients treated with abiraterone or enzalutamide
and evaluated for PSA response, 14 were AR-V7 positive
and eight were AR-V7 negative. The authors reported a
significant difference in PSA response rates between AR-V7
positive and AR-V7 negative men (8% vs. 63%, respectively,
for AR-V7 positive and AR-V7 negative patients). It is worth
noting that the same group subsequently identified four
AR-V7 positive patients with PSA response (defined by
greater than 50% PSA drop) from a total of 21 AR-V7 posi-
tive men, suggesting a positive AR-V7 test may not always
predict lack of PSA response (defined by greater than 50%
PSA drop) to abiraterone or enzalutamide [28]. Onstenk
et al. [29] measured AR-V7 transcript in blood samples with
more than 10 CTCs from men initiating cabazitaxel, and
detected AR-V7 in 55% patients (16/29). Consistent with
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treatment outcome as evaluated by PSA response, PFS, or
OS in this cohort of men treated with cabazitaxel.
Most recently, two studies demonstrated the feasibility
of detecting AR-V7 mRNA transcript in blood without the
CTC enrichment step [30,31]. In the study by Liu et al. [30],
a total of 46 CRPC patients were evaluated for AR-V7 by the
whole blood RNA assay. AR-V7 was detected in 68% of the
samples. Among patients compatible with evaluation of
biomarker association with history of treatment, AR-V7
status was strongly associated with prior treatment with
second-line AR-targeting therapies (abiraterone, enzaluta-
mide, and ketoconazole). Another AR splice variant,
ARV567ES [32], was also detected in a smaller proportion
(w30%) of patient samples, most of which were concur-
rently positive for AR-V7. This study did not evaluate as-
sociation between AR-V7 status and treatment outcome. In
another study by Todenhofer et al. [31], a cut-off value was
established from an initial cohort of 27 mCRPC and 33 non-
cancer controls for AR-V7 positivity determination. A vali-
dation cohort of 37 men initiating abiraterone was evalu-
ated for association between baseline biomarker status
determined by the whole-blood RNA assay with treatment
outcome. AR-V7 was positive in four samples and negative
in 33 samples in this validation cohort. Positive AR-V7 status
was associated with worse treatment outcome, as evalu-
ated by PSA response rate (0% vs. 42%, p Z 0.27, in AR-V7
positive vs. AR-V7 negative men), PSA-PFS (0.7 months vs.
4.0 months, p < 0.001, in AR-V7 positive vs. AR-V7 negative
men), and median OS (5.5 months vs. 22.1 months,
p < 0.001, in AR-V7 positive vs. AR-V7 negative men).
4. AR-V7 mRNA detection by RISH
In our initial clinical study [22], we also reported a tissue-
based mRNA test for AR-V7 by RNA in situ hybridization
(RISH). In a very limited sample set for which both metastatic
biopsy and CTC samples were collected at the same time
points, tissue RISH data were concordant with CTC findings
from the same patient [22]. Guedes et al. [33] recently
evaluated the analytical validity of this tissue-based AR-V7
RISH in an expanded sample set. Notably, AR-V7 mRNA was
mostly undetectable in pre-ADT specimens. A recent study
by Saylor et al.[34] further conformed this finding. In the
study by Saylor et al.[34], AR-V7 was positive by RISH in all 12
mCRPC specimens collected after treatment with second-
line AR targeting agents, but only one out of 30 prostate
cancer specimens from untreated men (i.e., radical prosta-
tectomy specimens) was positive. In this study, an additional
set of 22 specimens collected from metastatic prostate
cancer prior to first-line ADT was analyzed. Although the
sample size was small, AR-V7 was more frequently detected
in those with shorter duration of response to first-line ADT
(6/9 positive vs. 4/13 positive in short responder vs. long
responders), and there was a trend for positive association
between AR-V7 detection and OS and disease-specific sur-
vival in this pre-ADT cohort. Collectively, these findings
suggest that RISH-based AR-V7 test may be feasible in clinical
settings where tissue samples can be made available.
Although metastatic biopsies are not routinely collected
from men with metastatic prostate cancer, it is possible thatRISH may be applied to CTC samples, upon further refine-
ment of the RISH test following immobilization of nucleated
cells (including CTC) onto standard slides.
5. AR-V7 protein detections in CTCs
AR-V7 protein detection requires an AR-V7-specific anti-
body. A mouse monoclonal anti-AR-V7 antibody was
described and characterized in our initial studies [18,23,35]
and has been made available to the research community.
This antibody has not been optimized for immunohisto-
chemistry (IHC) and used in diagnostic settings [20]. Most
recently, Welti et al. [36] conducted analytical and clinical
evaluation of a new anti-AR-V7 rabbit monoclonal antibody
using tissue specimens. In analytical studies, the antibody
detected the AR-V7 protein but also a non-specific molecule
in some cell lines and tissue samples. In biopsy specimens
derived frommenwith CSPC and CRPC (both before and after
second-line AR-targeting therapies), there was a significant
and progressive increase of AR-V7 IHC score in CRPC (nZ 37)
(when compared to CSPC) and CRPC collected after treat-
ment with abiraterone and enzalutamide (when compared
to CRPC collected before abiraterone and enzalutamide). An
antibody against the AR N-terminal domain (AR-NTD) was
also used in the study. In CRPC (nZ 37), AR-V7 protein levels
and AR-V7/AR-NTD ratios was associated with shorter OS.
Using the rabbit anti-AR-V7 monoclonal antibody,
Scher et al.[37] evaluated AR-V7 protein expression in
liquid biopsies from men with mCRPC initiating treat-
ments with abiraterone, enzaltamide, or taxane chemo-
therapies. To make the CTC samples compatible with IHC,
the EPIC Sciences (San Diego, California) CTC platform
was used. The EPIC platform involves immobilization of
blood cells (including CTC) after red blood cell lysis,
ensuring all CTCs are captured. This is followed by CTC
identification and IHC using the anti-AR-V7 monoclonal
antibody. In this study, AR-V7 protein positive CTCs were
found in 18% of blood samples collected from men with
mCRPC at treatment baseline (n Z 191). Positive detec-
tion rates varied according to number of lines of therapy
patients received at the time of sample collection,
ranging from 3% (2 of 67) prior to first-line therapy, 18% (9
of 50) prior to second-line therapy, and 31% (23 of 74)
prior to prior to third and subsequent lines of therapies.
Consistent with clinical association between AR-V7 and
treatment outcome demonstrated in our previous studies
[22,25], detection of AR-V7 positive CTC was associated
with worse outcome in all measures, including PSA
response, rPFS, time on therapy, and OS, in men treated
with AR-targeting therapies (n Z 128). However, AR-V7
detection was not associated with most of these
outcome measures in men treated with taxane chemo-
therapies (n Z 63) (following collection of baseline sam-
ples). In AR-V7 positive men, those treated with taxanes
had longer median survival than those treated with AR-
targeting therapies, even though taxanes are adminis-
trated in later stages of disease with a significantly higher
AR-V7 positive rate (w29%, 18 of 63 samples) at treatment
baseline relative to the detection rate in men initiating
AR-targeting agents (w13%, 16 of 128 samples). In AR-V7
negative men, such difference in outcome by treatment
174 J. Luocategory was not observed. Therefore, both AR-V7 mRNA
and protein detection in CTC has been associated with
treatment-specific outcome. Collectively, these studies
support further development of AR-V7 as a non-invasive
treatment-specific biomarker in men underdoing
standard-of-care treatments for mCRPC.
6. Detection of AR amplification and AR mutation
TheAR gene is located in the X chromosome and normally has
only one copy in a male genome. However, the AR gene is
very commonly and specifically amplified/mutated in
mCRPC, suggesting that these AR DNA aberrations are ac-
quired alterations following ADT. AR amplification may
contribute to elevated levels of AR protein thatmay sensitize
AR to lower levels of androgens in treated patients, and
mutated AR may be activated by weak androgenic ligands,
nonandrogenic ligands, or anti-androgens. Both AR muta-
tions and AR amplification/gain can be detected in CtDNA
samples from men with mCRPC, and utilized to evaluate
clinical association and treatment induced tumor evolution
[38]. Recently, a larger scale study focused on these AR ab-
errations in patients receiving abiraterone [39]. In this study,
next-generation sequencing (NGS) data were collected from
a total of 274 CtDNA samples from 97 patients. Because
CtDNA represented a fraction of total cell-free DNA (CfDNA),
a cut-off of 7.5%was used to qualify the samples for analysis,
leading to data points from 217 informative samples from 80
patients. Among the 217 sampleswith CtDNA fraction greater
than 7.5%, 81 were positive for AR gain, and 26 were positive
for AR mutations, including L702H, T878A/S, H875Y, and
W742C/L. Notably, detection of AR gain and mutations
appear to bemutually exclusive,with only three cases having
both AR gain and AR mutation. Overall, 114 of 217 samples
were positive for these AR aberrations. Among the 80 base-
line samples, 36 were positive for AR aberrations. These AR
aberration-positive patients were less likely to have PSA
response and had shorter OS and PFS compared to patients
without any of the AR aberrations.
Azad et al. [40] recently reported detection of AR gain/
amplification in 45% (28/62) CtDNA samples from 62 mCRPC
patients progressing on abiraterone (n Z 29), enzalutamide
(n Z 19), and other systemic therapies. They also detected
AR ligand-binding domain (LBD) mutations in 11 of 62 pa-
tients (18%). Among these 62 patients, 39 were treated with
enzalutamide as the subsequent line of therapy following
the sampling time points for AR analysis, allowing investi-
gation of association between pretreatment AR biomarker
status and clinical outcomes on enzalutamide. They re-
ported lower rates of PSA response (PSA decline greater than
30%) (20% vs. 60%, pZ 0.013) in patients with detectable AR
aberrations (n Z 19) relative to those without AR aberra-
tions (n Z 20). In this cohort, median clinical/radiographic
PFS after enzalutamide was also worse in AR marker positive
patients (2.3 months) when compared with AR marker
negative patients (7.0 months) (p < 0.001, log-rank test).
In a follow-up study from the same group Wyatt et al.[41]
examined AR DNA alterations in CtDNA samples from 65 men
receiving enzalutamide. Array comparative genomic hy-
bridization was used to detect AR copy number alterations
and targeted deep sequencing was used to detect ARmutations. Samples were collected at treatment baseline
(n Z 65), at 12 weeks post baseline without disease pro-
gression (n Z 30), and at the time of progression (n Z 30).
AR copy number alterations and/or AR mutations were
detected in 48% (31 of 65) and 60% (18 of 30) of baseline and
progression samples, while such events were rarely detected
in samples collected at 12 weeks, possibly due to lack of
detectable CtDNA in the majority of responding patients.
Consistent with findings from Romanel et al. [39], detection
of AR amplification and mutation was mutually exclusive in
this cohort, suggesting that AR mutation and AR amplifica-
tion may be independent drivers of CRPC progression. In this
study, AR alterations detected in CtDNA was associated with
worse treatment outcome, and there was an increase in
detection frequency in progression samples.
Collectively, these findings suggest that detection of AR
DNA aberrations (AR amplification/gain/mutation) can be
achieved non-invasively and is associated with worse
treatment outcome. However, more studies are warranted
to determine whether the difference in outcome between
groups with positive and negative CtDNA AR aberration
status is treatment-specific, i.e., whether the biomarker
status is also associated with outcome in the setting of
taxane chemotherapies.
7. Detection of DNA damage repair pathway genes
Recently a number of actionable mutations are character-
ized in details in metastatic biopsies from men with mCRPC
[15]. One of the most exciting findings from this study is the
detection of mutations involving the DNA damage response
pathway in both germline and tumor samples at frequencies
that were substantially higher than anticipated. It is now
clear that patients harboring these mutations have a
favorable response pattern if treated with poly(ADP)-ribose
polymerase (PARP) inhibitors or other agents targeting the
DNA damage response pathway under the concept of
“synthetic lethality” [42]. Although initial reports relied on
tissues for mutation detection [15,42], such mutations may
be detected by a non-invasive method in mCRPC patients
using CtDNA as the biosource. Importantly, in a significant
proportion of tumor samples with such mutations, a germ-
line mutation may be present and can be readily evaluated
using germline DNA even before full manifestation of the
disease (e.g., at the time of initial diagnosis) [43]. There-
fore, it is possible that genetic testing may provide an op-
portunity to eradicate the lethal tumor clones early on
(e.g., at the time of diagnosis) with agents targeting the
DNA damage response/repair pathway in newly diagnosed
patients harboring these actionable mutations.
8. Future directions for biomarker research in
metastatic prostate cancer
In spite of the advances that have been made, biomarker
research and clinical translation is still a nascent field. Going
forward, a few frontiers in biomarker studies of metastatic
prostate cancer are identified in order to realize the po-
tential of liquid biopsies and technological advances for the
development of non-invasive treatment-specific biomarkers
for metastatic prostate cancer. First, comprehensive
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size, well-defined patient cohorts may further define the
treatment selections markers. Platforms that allow inte-
grated studies such as those demonstrated by Sperger et al.
[44] may help to achieve this goal. Second, in the setting of
potent AR-targeting therapies, it is critical to develop non-
invasive neuroendocrine/small cell prostate cancer
markers. Neuroendocrine/small-cell prostate carcinomas
are resistant to standard AR agents. Recent studies provided
a molecular signature that may allow development of bio-
markers for this increasingly important subgroup of tumors
[45]. In particular, non-invasive markers may be developed
by targeting RNA (expression level, variant detection, non-
coding RNA, etc.), or DNA (mutation, methylation), and
may utilize a variety of biosources (CtDNA, CTC, exosomem,
platelets). Last, since many agents approved for mCRPC
patients are undergoing evaluation in patients with mCSPC,
it is reasonable to expect that the treatment landscape for
mCSPC may undergo changes similar to that for mCRPC in
the years to come. Indeed, docetaxel added to first-line ADT
has recently become the standard-of-care for mCSPC given
the survival benefit especially in high-volume patients [46].
Collectively, the changing clinical landscape for metastatic
prostate cancer and the limited utility of existing prognostic
markers highlight an urgent need to develop biomarkers that
can inform treatment selection in all men with metastatic
prostate cancer.
9. Conclusion
In this review, recent evidence supporting the clinical utility
of biomarkers compatible with non-invasive sampling in the
setting of mCRPC was presented. Biomarker candidates
included AR-V7, AR amplification/gain/mutation, and
mutated DNA damage response genes. A few frontiers of
biomarker research were identified. Well-designed bio-
markers studies will require substantial investment in marker
identification and qualification, assay platform, and access
to clinical resources. Although the AR-V7 test represent one
example of a rationally qualified marker beginning to benefit
men with mCRPC, substantial efforts in discovery, validation,
and implementation are still needed in order to further
optimize treatment selection. Discovery will be facilitated
by technological advances in NGS and the ability to analyze
small amount of biomolecules obtained from liquid biopsies.
Validation studies may include both analytical validation as
well as clinical utility studies in prospective trials, and may
require the development of novel testing platforms. While
commercial interest and regulatory approval may facilitate
clinical implementation of a test in specific intended use
settings, laboratory-developed tests (LDTs) may also be
implemented in clinical testing labs prior to FDA approval. It
is fully envisioned that non-invasive actionable biomarkers
will become indispensable assets in maximizing the benefit
of existing therapies as well as clinical development of new
agents for metastatic prostate cancer.
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